{"doi":"10.1002/chir.21995","title":"Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group","abstract":"<jats:title>Abstract</jats:title><jats:p>This work reports the result of the enantioselective disposition of pantoprazole, omeprazole, and lansoprazole in a same group of Brazilian health subjects. Ten nongenotyped healthy subjects were used for this study. Each subject received a single oral dose of 80 mg of pantoprazole, 40 mg of omeprazole, and 30 mg of lansoprazole, and the plasma concentrations of the enantiomers were measured for 8 h postdose. For pantoprazole and omeprazole, among the 10 volunteers investigated, only one volunteer (Subject # 4) presented higher plasma concentrations of the (+)‐enantiomer than those of (−)‐enantiomer. Nevertheless, the area under the concentration–time curve of the (+)‐lansoprazole was higher than those the (−)‐lansoprazole for all subjects. The comparison of proton pump inhibitors' enantiomers disposition from a single group volunteer demonstrated that pantoprazole and omeprazole can be used to differentiate extensive from poor CYP2C19 metabolizer while lansoprazole cannot do it. Chirality, 2012. © 2012 Wiley Periodicals, Inc.</jats:p>","journal":"Chirality","year":2012,"id":655156,"datarank":0.3453877639491069,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.0,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1710093,"name":"Regina V. Oliveira","orcid":null,"position":1,"is_corresponding":false},{"id":1710094,"name":"Gilberto C.R. Bernasconi","orcid":null,"position":2,"is_corresponding":false},{"id":1710095,"name":"Quezia B. Cass","orcid":null,"position":3,"is_corresponding":false},{"id":1710092,"name":"Neila M. Cassiano","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group","abstract":"<jats:title>Abstract</jats:title><jats:p>This work reports the result of the enantioselective disposition of pantoprazole, omeprazole, and lansoprazole in a same group of Brazilian health subjects. Ten nongenotyped healthy subjects were used for this study. Each subject received a single oral dose of 80 mg of pantoprazole, 40 mg of omeprazole, and 30 mg of lansoprazole, and the plasma concentrations of the enantiomers were measured for 8 h postdose. For pantoprazole and omeprazole, among the 10 volunteers investigated, only one volunteer (Subject # 4) presented higher plasma concentrations of the (+)‐enantiomer than those of (−)‐enantiomer. Nevertheless, the area under the concentration–time curve of the (+)‐lansoprazole was higher than those the (−)‐lansoprazole for all subjects. The comparison of proton pump inhibitors' enantiomers disposition from a single group volunteer demonstrated that pantoprazole and omeprazole can be used to differentiate extensive from poor CYP2C19 metabolizer while lansoprazole cannot do it. Chirality, 2012. © 2012 Wiley Periodicals, Inc.</jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22344845","pmcid":null,"openalex_id":"https://openalex.org/W1977389196","authors":[],"funders":[],"total_grants":0,"fwci":0.8076,"citation_percentile":0.74654937,"influential_citations":0,"citation_trend":[{"year":2013,"count":1},{"year":2014,"count":2},{"year":2018,"count":1},{"year":2021,"count":1},{"year":2022,"count":1},{"year":2023,"count":3}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fchir.21995","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/chir.21995","host_type":"publisher"},{"url":"https://doi.org/10.1002/chir.21995","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22344845","host_type":"repository"}],"fields_of_study":["Antibiotics Pharmacokinetics and Efficacy","Pharmacogenetics and Drug Metabolism","Ion Transport and Channel Regulation"],"mesh_terms":["Pantoprazole","Adolescent","Adult","Brazil","Humans","Middle Aged","Omeprazole","Stereoisomerism","Substrate Specificity","2-Pyridinylmethylsulfinylbenzimidazoles","Proton Pump Inhibitors","Young Adult","Lansoprazole"],"keywords":["Lansoprazole","Omeprazole","Pantoprazole","Chemistry","Proton-pump inhibitor","Volunteer","Pharmacology","Enantiomer","CYP2C19","Stereochemistry","Medicine","Biochemistry","Metabolism"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"No poverty"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T09:51:54.422463Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}